Atrasentan - Chinook Therapeutics
Alternative Names: A 147627; A-1476271; Abbott 147627; ABT-147627; ABT-627; Atrasentan hydrochloride; CHK-01; EXV-811; Vanrafia; XinlayLatest Information Update: 07 Apr 2025
At a glance
- Originator Abbott Laboratories
- Developer Abbott Laboratories; AbbVie; Chinook Therapeutics
- Class Amides; Anti-inflammatories; Antineoplastics; Benzodioxoles; Carboxylic acids; Ethers; Heart failure therapies; Pyrrolidines; Small molecules; Toluenes; Vascular disorder therapies
- Mechanism of Action Endothelin A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered IgA nephropathy
- Phase III Atherosclerosis
- Phase II Diabetic nephropathies; Focal segmental glomerulosclerosis; Hereditary nephritis
- Discontinued Adenocarcinoma; Brain cancer; Coronary artery restenosis; Heart failure; Lung cancer; Ovarian cancer; Prostate cancer; Renal cancer